AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

The global breast cancer therapeutics market is expected to grow from US$ 31.07 billion in 2022 to US$ 63.9 billion by 2030, ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...

Read also: AstraZeneca-Daiichi Sankyo Enhertu recommended for approval in EU for patients with HER2-low or HER2-ultralow metastatic breast cancer Medical Dialogues team had earlier reported that the ...

Additionally, AstraZeneca received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending the approval of Enhertu for certain ...

In other recent news, AstraZeneca has reported positive financial and operational developments. The company announced significant advancements in breast cancer treatment, with its drug Enhertu ...